Mayo Clinic Laboratories, Lucence partner to expand access to liquid biopsy

Lab Test Tube Dna Blood Social

Mayo Clinic Laboratories and oncology diagnostics firm Lucence have announced a strategic collaboration to expand international access to Lucence's liquid biopsy technology.

Under the agreement, Lucence will provide access to its LiquidHallmark liquid biopsy through Mayo Clinic Laboratories, the companies shared in a statement.

LiquidHallmark is an amplicon-based next-generation sequencing assay developed to target both circulating DNA and RNA. The test results include detailed descriptions of each finding along with its role in the patient's cancer type, existing functional evidence, and associated clinical trials, as well as targeted therapies based on the genomic results, Lucence said. The results also provide graphical maps for understanding cancer genomic profiles and tracking tumor changes over time.

"Working with Mayo Clinic Laboratories will advance our shared goal of making innovative cancer tests available to benefit everyone globally," said Min-Han Tan, PhD, CEO and medical director of Lucence. "Combining Lucence's liquid biopsy testing with Mayo Clinic Laboratories' broad reach and expertise means that healthcare providers everywhere can be empowered with important information to improve personalized cancer care," Tan said.

Palo Alto, CA-based Lucence has Clinical Laboratory Improvement Amendments (CLIA)-licensed and College of American Pathologists (CAP)-accredited laboratories in California and Singapore.

Financial details of the agreement were not disclosed. Mayo Clinic Laboratories noted that it is a for-profit wholly owned subsidiary of Mayo Clinic; Mayo Clinic will use any revenue from the collaboration to support its not-for-profit work in patient care, education, and research.

Page 1 of 42
Next Page